Minimal residual disease (MRD) at time of complete remission is commonly detected in acute myeloid leukemia (AML) patients age ≥ 60 years and significantly impacts outcome based on post-remission treatment strategies: Prospective analysis of ECOG-ACRIN (E-A) E2906 phase III trial Meeting Abstract

  

Authors:	Foran, J. M.; Sun, Z.; Paietta, E.; Racevskis, J.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Altman, J. K.; Al-Kali, A.; Zheng, H.; Pratz, K. W.; Broun, E. R.; Powell, B. L.; O'Dwyer, K. M.; Godwin, J.; Zhang, Y.; Tallman, M. S.; Luger, S.; Litzow, M. R.
Abstract Title:	Minimal residual disease (MRD) at time of complete remission is commonly detected in acute myeloid leukemia (AML) patients age ≥ 60 years and significantly impacts outcome based on post-remission treatment strategies: Prospective analysis of ECOG-ACRIN (E-A) E2906 phase III trial
Meeting Title:	60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2018 Dec 1-4
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2018-11-29
Language:	English
ACCESSION:	WOS:000454837601146
PROVIDER:	wos
DOI:	10.1182/blood-2018-99-113950
Notes:	Meeting Abstract: 437 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/145187